Text Size

Good EULAR Response in Patients With Early Rheumatoid Artrhitis (EARLY RA)

This study is currently recruiting participants.
Verified May 2013 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01558089
First received: February 15, 2012
Last updated: May 14, 2013
Last verified: May 2013
History of Changes
  Purpose

This open-label, prospective, observational study will evaluate the clinical response to etanercept + methotrexate therapy in patients with moderate to severe rheumatoid arthritis, as prescribed by the rheumatologist in a normal clinical setting in Greece


Condition Intervention Phase
Rheumatoid Arthritis
 Drug: etanercept
Drug: methotrexate
 Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Ability to Achieve a Good Eular Response in Patients With Moderate-to-severe Active Early Rheumatoid Arthritis Who Satisfy the New ACR/EULAR Classification Criteria Receiving Etanercept + MTX in Real World Clinical Practice in Greece

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Percentage of patients that achieved Good EULAR response based on DAS28 EULAR response criteria [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline in each component of DAS28 [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]
  • Change from baseline in HAQ-DI [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]
  • Change from baseline in EQ-5D [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: February 2013
Estimated Study Completion Date: February 2015
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
etanercept + methotrexate Drug: etanercept
according to SmPC and clinical practice
Drug: methotrexate
according to SmPC and clinical practice

Detailed Description:

All subjects enrolled should meet the usual prescribing criteria for Etanercept as per the local product information and should be entered into the study at the investigator's discretion

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients with rheumatoid arthritis who fulfill the inclusion/exclusion criteria

Criteria

Inclusion Criteria:

  1. signed and dated informed consent document
  2. 18 years of age and older at the time of consent
  3. Patients with moderate-to-severe active rheumatoid arthritis, who satisfy the 2010 Rheumatoid Arthritis Classification Criteria
  4. Patients who have been prescribed for first time to receive treatment with MTX + Etanercept prior to enrollment to this study, following routine clinical practice and according to the approved SmPC,
  5. Patients with DAS28 ≥ 3.2
  6. Duration of disease symptoms ≥ 6 weeks and ≤2 years
  7. Failure to respond to prior DMARDs including MTX monotherapy according to routine clinical practice.

Exclusion Criteria:

  1. Contraindications according to the SmPC
  2. History of or present anti-TNFa or other biologic therapy for the treatment of RA
  3. Known significant concurrent medical disease according to investigator's opinion and the current SmPC
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01558089

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021

Locations
Greece
G. Papanikolaoy Not yet recruiting
Thessaloniki, Exochi, Greece, 570 10
Laiko General Peripheral Hospital Not yet recruiting
Athens, Greece, 115 27
Peripheral University General Hospital of Larissa Recruiting
Larissa, Greece, 41 222
Papageorgiou General Hospital of Thessaloniki / Rheumatology department Not yet recruiting
Thessaloniki, Greece, 56429
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01558089     History of Changes
Other Study ID Numbers: B1801138
Study First Received: February 15, 2012
Last Updated: May 14, 2013
Health Authority: Greece: Ethics Committee

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Methotrexate
TNFR-Fc fusion protein
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
 Therapeutic Uses
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics

ClinicalTrials.gov processed this record on May 16, 2013